|
| |
Neuroendocrine TumorsDownload PDF containing detailed information.
Recent Publications on Neuroendocrine Tumors: |  |
Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy.
ABSTRACT: The mammalian target of rapamycin (mTOR) is an intracellular... | 29th October, 2009
|
| J Hematol Oncol. 2009 Oct 27;2(1):45.
DOI Direct Link |
Patient-reported outcomes in subjects with neuroendocrine tumors of the pancreas.
AIM: To assess the patient-reported outcomes (PROs) of pancreatic... | 28th October, 2009
| Department of Digestive Diseases and Internal Medicine,
| World J Gastroenterol. 2009 Oct 28;15(40):5067-73.
|
Pitfalls in the diagnosis of neuroendocrine tumors: atypical clinical and radiological findings as cause of medical mistakes.
AIMS AND BACKGROUND: Carcinoids are infrequent neoplasms arising from... | 28th October, 2009
| Unit of Medical Oncology2, Centro di Riferimento per lo Studio e la Cura
| Tumori. 2009 Jul-Aug;95(4):501-7.
|
Twenty-Five-Year Follow-up for Liver Resection: The Personal Series of Dr. Joseph G. Fortner.
BACKGROUND:: Liver resection is performed for many types of malignancies.... | 27th October, 2009
| From the Memorial Sloan-Kettering Cancer Center, New York, NY.
| Ann Surg. 2009 Oct 21.
DOI Direct Link |
Biochemical testing for neuroendocrine tumors.
In this review, we focus on the use of biochemical markers for the... | 27th October, 2009
| Eastern Virginia Medical School, Strelitz Diabetes Research Center,
| Pancreas. 2009 Nov;38(8):876-89.
DOI Direct Link |
→View more research publications. |
Press Releases About Neuroendocrine Tumors:
|
 |
| AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer |
2nd November, 2009 |
AETERNA ZENTARIS INC. |
Preliminary evaluation after completion of treatment phase shows that
primary efficacy endpoint has been met for patients with advanced-stage
platinum-resistant, taxane-pretreated ovarian
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| Ascenta Therapeutics Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme |
26th October, 2009 |
Ascenta Therapeutics, Inc. |
MALVERN, Pa., Oct. 26 /PRNewswire/ -- Ascenta Therapeutics announced today that encouraging results from a Phase I dose-escalation study of two combination therapy regimens containing AT-101, an oral,
|
| Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer |
23rd October, 2009 |
Onyx Pharmaceuticals, Inc. |
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun
|
| NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma |
22nd October, 2009 |
NexGenix Pharmaceuticals Holdings, Inc. |
NEW YORK, Oct. 22 /PRNewswire/ -- NexGenix Pharmaceuticals Holdings, Inc. a privately-held biotechnology company with a portfolio of novel targeted therapies for oncology and neurodegenerative
|
Neuroendocrine Tumors Patents: |  |
| US Patent No. | Title |
| 7449549 | PRO9822 polypeptides |
| 7485308 | 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206, and 8843 molecules and uses therefor |
| 7488586 | PRO4409 polypeptides |
| 7488588 | Compounds related to or derived from GFR .alpha.4 and their use |
| 7488796 | PRO1269 polypeptides |
→View more patents. |
Companies working in the area of Neuroendocrine Tumors from Bioportfolio's Biocorporate database : | |
| Company Name | |
Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to...
www.tercica.com/ View full profile
| |
Molecular Insight Pharmaceuticals, Inc. is focused on the research, development and commercialization of innovative molecular imaging pharmaceuticals and targeted radiotherapeutics to diagnose, treat...
www.molecularinsight.com/ View full profile
| |
BioPortfolio Ltd. offers e-mail and postal lists for Neuroendocrine Tumors scientists - we have details of around 291 individuals working on Neuroendocrine Tumors .
This page has been viewed 450 times
Recent Search Terms used to find this page: neuroendocrine tumour, e-medicine | neuroendocrine tumors | neuroendocrine tumors news | neuroendocrine tumors of pancreas | neuroendrocrine 2009 | Predicting neuroendocrine tumor (carcinoid) neoplasia using gene expression profiling and supervised machine learning | video of pancreas neuroendocrine tumor | any new news on neuro endocrine tumors | neuroendocrine tumour patholgy | .
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Neuroendocrine Tumors across BioPortfolio, or for Neuroendocrine Tumors Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
